Online inquiry

IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8621MR)

This product GTTS-WQ8621MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8621MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4924MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ13458MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ13640MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ6188MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ7001MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ4459MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ15291MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ2621MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW